School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Diabetes Metab Syndr. 2024 Jun;18(6):103068. doi: 10.1016/j.dsx.2024.103068. Epub 2024 Jun 28.
Clinical evidence for early identification and diagnosis of liver cirrhosis (LC) caused by different types of liver disease is limited. We investigated this topic through a meta-analysis of quantitative metabolomics.
Four databases were searched until October 31, 2022 for studies comparing metabolite levels between patients with different types of liver disease and control individuals. A random-effects model was applied for the meta-analysis.
This study included 55 studies with 8266 clinical participants, covering 348 metabolites. In LC related to drug-induced liver injury (DILI), hepatitis B virus (HBV) infection, and non-alcoholic fatty liver disease (NAFLD), the primary bile acid biosynthesis (taurocholic acid: SMD, 1.08[0.81, 1.35]; P < 0.00001; glycocholic acid: SMD, 1.35[1.07, 1.62]; P < 0.00001; taurochenodeoxycholic acid: SMD, 1.36[0.94, 1.78]; P < 0.00001; glycochenodeoxycholic acid: SMD, 1.49[0.93, 2.06]; P < 0.00001), proline and arginine (l-proline: SMD, 1.06[0.53, 1.58]; P < 0.0001; hydroxyproline: SMD, 0.81[0.30, 1.33]; P = 0.002), and fatty acid biosynthesis (palmitic acid: SMD, 0.44[0.21, 0.67]; P = 0.0002; oleic acid: SMD, 0.46[0.19, 0.73]; P = 0.0008; stearic acid: SMD, 0.37[0.07, 0.68]; P = 0.02) metabolic pathways were significantly altered.
We identified key biomarkers and metabolic characteristics for distinguishing and identifying LC related to different types of liver disease, providing a new perspective for early diagnosis, disease monitoring, and precise treatment.
临床上对于不同病因导致的肝硬化（LC）的早期识别和诊断的证据有限。我们通过对定量代谢组学的荟萃分析来研究这个课题。
检索了四个数据库，截至 2022 年 10 月 31 日，以比较不同类型肝病患者和对照个体之间代谢物水平的研究。采用随机效应模型进行荟萃分析。
这项研究纳入了 55 项研究，共 8266 名临床参与者，涵盖 348 种代谢物。在药物性肝损伤（DILI）、乙型肝炎病毒（HBV）感染和非酒精性脂肪性肝病（NAFLD）相关的 LC 中，初级胆汁酸生物合成（牛磺胆酸：SMD，1.08[0.81，1.35]；P<0.00001；甘氨胆酸：SMD，1.35[1.07，1.62]；P<0.00001；牛磺鹅脱氧胆酸：SMD，1.36[0.94，1.78]；P<0.00001；甘氨鹅脱氧胆酸：SMD，1.49[0.93，2.06]；P<0.00001）、脯氨酸和精氨酸（l-脯氨酸：SMD，1.06[0.53，1.58]；P<0.0001；羟脯氨酸：SMD，0.81[0.30，1.33]；P=0.002）和脂肪酸生物合成（棕榈酸：SMD，0.44[0.21，0.67]；P=0.0002；油酸：SMD，0.46[0.19，0.73]；P=0.0008；硬脂酸：SMD，0.37[0.07，0.68]；P=0.02）代谢途径显著改变。
我们确定了用于区分和识别不同类型肝病相关 LC 的关键生物标志物和代谢特征，为早期诊断、疾病监测和精准治疗提供了新视角。
